- Home
- FNLC vs PVLA Comparison
FNLC vs PVLA Comparison
Compare FNLC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- PVLA
- Stock Information
- Founded
- FNLC 1864
- PVLA 2015
- Country
- FNLC United States
- PVLA United States
- Employees
- FNLC N/A
- PVLA N/A
- Industry
- FNLC Major Banks
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- PVLA Health Care
- Exchange
- FNLC Nasdaq
- PVLA Nasdaq
- Market Cap
- FNLC 275.9M
- PVLA 308.2M
- IPO Year
- FNLC 1999
- PVLA N/A
- Fundamental
- Price
- FNLC $24.72
- PVLA $28.00
- Analyst Decision
- FNLC
- PVLA Strong Buy
- Analyst Count
- FNLC 0
- PVLA 6
- Target Price
- FNLC N/A
- PVLA $43.50
- AVG Volume (30 Days)
- FNLC 17.2K
- PVLA 91.8K
- Earning Date
- FNLC 04-16-2025
- PVLA 03-31-2025
- Dividend Yield
- FNLC 5.81%
- PVLA N/A
- EPS Growth
- FNLC N/A
- PVLA N/A
- EPS
- FNLC 2.43
- PVLA N/A
- Revenue
- FNLC $79,740,000.00
- PVLA N/A
- Revenue This Year
- FNLC N/A
- PVLA N/A
- Revenue Next Year
- FNLC N/A
- PVLA N/A
- P/E Ratio
- FNLC $10.22
- PVLA N/A
- Revenue Growth
- FNLC 0.35
- PVLA N/A
- 52 Week Low
- FNLC $21.77
- PVLA $6.20
- 52 Week High
- FNLC $31.05
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- FNLC 42.04
- PVLA N/A
- Support Level
- FNLC $24.80
- PVLA N/A
- Resistance Level
- FNLC $25.33
- PVLA N/A
- Average True Range (ATR)
- FNLC 0.41
- PVLA 0.00
- MACD
- FNLC 0.02
- PVLA 0.00
- Stochastic Oscillator
- FNLC 35.85
- PVLA 0.00
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.